Salvage therapies used in TCR patients who relapsed from novel immunotherapy
| . | CAR-T (n = 17) . | BiAbs (n = 21) . |
|---|---|---|
| BiAbs, n (%) | 9 (47.4) | 6 (28.6) |
| BCMA, n | 0 | 0 |
| GPRC5D, n | 6 | 3 |
| FcRH5, n | 2 | 1 |
| BCMA + GPRC5D, n | 1 | 1 |
| NK, n | 0 | 1 |
| IMiDs-based schemes, n (%) | 1 (5.3) | 7 (33.3) |
| PCd | 0 | 5 |
| PVd | 1 | 1 |
| Celmod | 0 | 1 |
| PIs-based schemes, n (%) | 1 (5.3) | 4 (19.0) |
| VCd, n | 0 | 1 |
| SVd, n | 0 | 1 |
| BendaVd, n | 0 | 1 |
| Kd, n | 0 | 1 |
| KCd, n | 1 | 0 |
| Anti-CD38 moAb-based schemes, n (%) | 1 (5.3) | 1 (4.8) |
| Daratumumab, n | 0 | 1 |
| DRd, n | 1 | 0 |
| Allo-SCT, n (%) | 1 (5.3) | 0 (0.0) |
| BCMA CAR-Ts, n (%) | 1 (5.3) | 1 (4.8) |
| Venetoclax, n (%) | 1 (5.3) | 1 (4.8) |
| Polychemotherapy, n (%) | 2 (10.5) | 1 (4.8) |
| . | CAR-T (n = 17) . | BiAbs (n = 21) . |
|---|---|---|
| BiAbs, n (%) | 9 (47.4) | 6 (28.6) |
| BCMA, n | 0 | 0 |
| GPRC5D, n | 6 | 3 |
| FcRH5, n | 2 | 1 |
| BCMA + GPRC5D, n | 1 | 1 |
| NK, n | 0 | 1 |
| IMiDs-based schemes, n (%) | 1 (5.3) | 7 (33.3) |
| PCd | 0 | 5 |
| PVd | 1 | 1 |
| Celmod | 0 | 1 |
| PIs-based schemes, n (%) | 1 (5.3) | 4 (19.0) |
| VCd, n | 0 | 1 |
| SVd, n | 0 | 1 |
| BendaVd, n | 0 | 1 |
| Kd, n | 0 | 1 |
| KCd, n | 1 | 0 |
| Anti-CD38 moAb-based schemes, n (%) | 1 (5.3) | 1 (4.8) |
| Daratumumab, n | 0 | 1 |
| DRd, n | 1 | 0 |
| Allo-SCT, n (%) | 1 (5.3) | 0 (0.0) |
| BCMA CAR-Ts, n (%) | 1 (5.3) | 1 (4.8) |
| Venetoclax, n (%) | 1 (5.3) | 1 (4.8) |
| Polychemotherapy, n (%) | 2 (10.5) | 1 (4.8) |
Allo-SCT, allogeneic stem cell transplantation; BCMA, B-cell maturation antigen; Benda, bendamustine; C, cyclophosphamide; Celmod, Cereblon E3 Ligase Modulatory Drugs; DRd, daratumumab lenalidomide dexamethasone; FcRH5, Fc receptor homolog 5; GPRC5D, G protein–coupled receptor class C group 5 member D; Kd, carfilzomib dexamethasone; KCd, carfilzomib cyclophosphamide dexamethasone; NK, natural killer lymphocyte; P, pomalidomide; SVd, Selinexor bortezomib dexamethasone; VCd, bortezomib cyclophosphamide dexamethasone.